Streetbeat News

Price Targets

SRC

Janney Montgomery Scott analyst Robert Stevenson has downgraded Spirit Realty Cap (NYSE:SRC) from Buy to Neutral and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:30 pm

MTCH

Barclays analyst Mario Lu has maintained an Overweight rating on Match Group (NASDAQ:MTCH) but lowered the price target from $56 to $45.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:29 pm

BMY

Daiwa Capital analyst Narumi Nakagiri has downgraded Bristol-Myers Squibb (NYSE:BMY) from Outperform to Neutral and lowered the price target from $68 to $54.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:28 pm

MTZ

Barclays analyst Adam Seiden maintains an Overweight rating on MasTec (NYSE:MTZ) but has lowered the price target from $106 to $55.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:28 pm

LBTYA

Barclays analyst Maurice Patrick maintains an Equal-Weight rating on Liberty Global (NASDAQ:LBTYA) and lowers the price target from $21 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:26 pm

CFLT

Canaccord Genuity analyst Kingsley Crane has downgraded Confluent (NASDAQ:CFLT) from Buy to Hold and set a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:26 pm

BMRN

BioMarin Pharmaceutical reported lower than expected Q3 revenue results and issued FY23 guidance. Following this, Cantor Fitzgerald and Barclays lowered their price targets on the stock, leading to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:26 pm

KMT

Barclays analyst Julian Mitchell has maintained an Equal-Weight rating on Kennametal (NYSE:KMT) and lowered the price target from $28 to $26.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:24 pm

IQV

Barclays analyst Luke Sergott maintains an Overweight rating on IQVIA Holdings (IQV) but has lowered the price target from $245 to $215.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:22 pm

IDXX

Barclays analyst Balaji Prasad maintains an Overweight rating on IDEXX Laboratories (NASDAQ:IDXX) and raises the price target from $590 to $592.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:21 pm